0001209191-14-008352.txt : 20140207
0001209191-14-008352.hdr.sgml : 20140207
20140207160400
ACCESSION NUMBER: 0001209191-14-008352
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140205
FILED AS OF DATE: 20140207
DATE AS OF CHANGE: 20140207
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Connolly Thomas
CENTRAL INDEX KEY: 0001453943
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 14584355
MAIL ADDRESS:
STREET 1: 717 FIFTH AVENUE
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-02-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001453943
Connolly Thomas
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP, Human Resources
Common Stock
2014-02-05
4
A
0
11875
0.01
A
15647
D
Common Stock
2014-02-05
4
M
0
938
45.11
A
16585
D
Common Stock
2014-02-05
4
S
0
200
76.82
D
16385
D
Common Stock
2014-02-05
4
S
0
738
77.83
D
15647
D
Common Stock
150
I
401(k)
Employee Stock Option (right to buy)
77.31
2014-02-05
4
A
0
62750
0.00
A
2024-02-04
Common Stock
62750
62750
D
Employee Stock Option (right to buy)
45.11
2014-02-05
4
M
0
938
0.00
D
2023-02-04
Common Stock
938
11250
D
Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.
Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14).
Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13).
The option vests in 16 quarterly installments from 02/05/2014.
The option vests in 16 quarterly installments from 02/05/2013.
Kenneth L. Horton, Attorney-In-Fact
2014-02-07